// App-Quantinova.ai

: Comparative Benefit of Adding a Biomarker Ubiquitously Available in Clinical Care to Validated Risk Assessment Models for the Identification of Hospitalized Medical Patients at Risk for 90‐day Hospital‐associated Venous Thromboembolism

Researchers

Presenter

  • S. Woller

Principal Investigators

  • S. Stevens

  • E. Wilson

  • J. Bledsoe

  • J. Lloyd

  • B. Horne

Medical Centers

  • Intermountain Medical Center, Murray, United States

  • University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, United States

  • Intermountain Medical Center, Murray, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved